Skip to content

Desaturation Validation of INVSENSOR00028

Desaturation Validation of INVSENSOR00028

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03704636
Enrollment
46
Registered
2018-10-15
Start date
2018-09-25
Completion date
2018-10-24
Last updated
2021-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

This study is designed to measure the trending accuracy of a noninvasive regional oximetry measurement of somatic oxygen saturation. Two large sensors (adult sensors) will be placed on the subject's forehead. Two investigational sensors (INVSENSOR00028) will be placed on the forearm of the volunteer. The values obtained by the INVSENSOR00028 will be compared to the reference value calculated from the arterial and venous blood measurements. Data will be collected from healthy adult subjects while undergoing a desaturation procedure wherein the concentration of oxygen inhaled is slowly reduced until the subject's arterial oxygen saturation is approximately 70%, while blood samples are drawn at prespecified reference points. The subject will then be returned to inhaling room air.

Interventions

DEVICEINVSENSOR00028

Noninvasive pulse oximeter sensor

Sponsors

Masimo Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject weighs a minimum of 110 lbs and no more than 250 lbs unless subject is over 6 feet tall. * Hemoglobin value is greater than or equal to 11 g/dL. * Baseline heart rate ≥ 45 bpm and ≤ 85 bpm. * CO value ≤ 2.0% FCOHb * Subject has a physical status of ASA I or II (American Society of Anesthesiology Class I; Healthy subjects without any systemic disease at all. American Society of Anesthesiology Class II; subjects with mild systemic disease) as it applies to the systemic disease portion of the classification. * Systolic Blood Pressure ≤ 140 mmHg and Diastolic Blood Pressure ≤ 90 mmHg. * Subject is able to read and communicate in English and understands the study and risks involved.

Exclusion criteria

* Subject is pregnant. * Subject smokes (smoking includes e-cigarette use). * Subject has a BMI \> 35 and has been classified as morbidly obese or at an increased risk for participation by a medical professional. * Subject has a history of fainting (vasovagal), blacking out or losing consciousness during or after a blood draw. * Subject has open wounds, inflamed tattoos or piercings, visible healing wounds. * Subject experiences frequent or severe headaches and/or migraine headaches. * Subject has known drug or alcohol abuse and/or use of recreational drugs. * Subject has experienced a concussion or head injury with loss of consciousness within the last year. * Subject has any chronic bleeding disorders (i.e. hemophilia). * Subject has any history of a stroke, myocardial infarction, seizures or heart attack. * Subject has any cancer or history of cancer (not including skin cancer). * Subject has a chronic neurological disease (i.e. multiple sclerosis, Huntington's Disease). * Subject has any cardiac dysrhythmia(s) (i.e. atrial fibrillation) and has not received clearance by their physician to participate. * Subject has a known neurological and/or psychiatric disorder (i.e. schizophrenia, bipolar disorder) that interferes with the subject's level of consciousness. * Subject has any medical condition which in the judgment of the investigator and/or medical staff, renders them ineligible for participation in this study (Discretion of investigator). * Subject has Wolff-Parkinson-White Syndrome or Stokes-Adams Syndrome. * Subject who has taken anticoagulant medication within the last 30 days. * Subject has taken opioid pain medication within 24 hours of start of study. * Subject has any type of infectious disease (i.e. Hepatitis, HIV, Tuberculosis, Flu, Malaria, Measles, etc.). * Subject is taking medications known to treat any type of infectious disease. * Subject has either signs or history of peripheral ischemia. * Subject has had invasive surgery within the past year- including but not limited to major dental surgery, gallbladder, heart, appendix, major fracture repairs (involving plates/ screws), jaw surgery, urinary tract surgery, plastic surgery, major ENT surgery, joint replacement or gynecological surgeries, heart surgery or thoracic surgery. * Subject has donated blood within the past 30 days. * Subject has symptoms of congestion, head colds, flu or other illnesses. * Subject experiences claustrophobia or has generalized anxiety disorder. * Subject has been in severe car accident(s) or a similar type of accident(s) requiring hospitalization within the last 12 months. * Subject has chronic unresolved asthma, lung disease or respiratory disease. * Subject is allergic to lidocaine, latex, adhesives, or plastic. * Subject has heart conditions, insulin-dependent diabetes or uncontrolled hypertension. * Subject has given vaginal delivery, had a pregnancy terminated, a miscarriage with hospitalization, or had a C-section within the last 6 months. * Subject intends to participate in any heavy lifting, repetitive movement of their wrist (including riding a motorcycle) or exercise (working out, riding a bike, riding a skate board etc.), or any activity that will put additional stress on the wrist within 24 hours of the study. * Discretion of investigator/study staff.

Design outcomes

Primary

MeasureTime frameDescription
Oxygen Saturation (rSO2) Accuracy of Sensor1-5 hoursThe Trending accuracy of the INVSENSOR00028 will be evaluated relative to the reference value calculated from the arterial and venous blood measurements.

Countries

United States

Participant flow

Pre-assignment details

Of the 46 enrolled participants, 23 met inclusion criteria and proceeded to the study. The remainder of the enrolled participants include screen failures and subjects that did not proceed due to time constraints.

Participants by arm

ArmCount
Test Subject
All subjects who are enrolled into the test group and participate in data collection receive the noninvasive INVSENSOR00028 sensor. INVSENSOR00028: Noninvasive pulse oximeter sensor
20
Total20

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyInadequate Venous Flow3

Baseline characteristics

CharacteristicTest Subject
Age, Customized
18 to 50 years old
20 Participants
Age, Customized
< 18 years old
0 Participants
Age, Customized
> 50 years old
0 Participants
Race/Ethnicity, Customized
Asian or Pacific Islander
2 Participants
Race/Ethnicity, Customized
Black or African American
6 Participants
Race/Ethnicity, Customized
Caucasian
8 Participants
Race/Ethnicity, Customized
Hispanic
4 Participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 20
other
Total, other adverse events
3 / 20
serious
Total, serious adverse events
0 / 20

Outcome results

Primary

Oxygen Saturation (rSO2) Accuracy of Sensor

The Trending accuracy of the INVSENSOR00028 will be evaluated relative to the reference value calculated from the arterial and venous blood measurements.

Time frame: 1-5 hours

Population: There is no apparent trend in either the Brachial or Flexor RSO2 data with respect to the control. Since there is no measurable trend, a numerical value for Trending Accuracy (as defined in the protocol) cannot be accurately determined.

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026